Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Inclusion Criteria: * Subjects currently enrolled in study 20050103, 20050136, or 20050244 * Subjects must sign the informed consent before any study specific procedures are performed Exclusion Criteria: * Developed sensitivity to mammalian cell derived drug products during the 20050103, 20050136, or 20050244 study * Currently receiving any unapproved investigational product other than denosumab * Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment * Subject (male or female) is not willing to use 2 highly effective contraception during treatment and for 7 months (women) or 10 months (men) after the end of treatment * Male subject with a pregnant partner who is not willing to use a condom during treatment and for additional 10 months after the end of treatment * Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures